Sei uscito con successo.

Ciao !
Logout

Trattamento delle piaghe da decubito

La sfida della gestione delle piaghe da decubito

Tutti vogliono evitare le ulcere da pressione. Negli ultimi anni sono stati compiuti notevoli progressi in quest'area. Ciononostante, le ulcere da pressione restano una sfida. B. Braun offre diverse soluzioni, tra cui prodotti per la cura della cute, la preparazione del letto della ferita e la gestione delle infezioni, nonché la gestione dell'essudato. Agire fin dall'inizio aiuta a prevenire l'aggravamento delle ulcere da pressione esistenti e a supportare il processo di guarigione.

Sei un operatore sanitario?

Cliccando "Confirm" dichiari di essere un operatore sanitario.


Se sei un paziente o un giornalista visita le pagine a te dedicate.

Conferma Sì, sono un operatore sanitario. Cancella No, non sono un operatore sanitario.
*esempi di barriere = slough, tessuto necrotico e/o biofilm
Gestione delle ulcere da pressione di 1° stadio

Gestione delle ulcere da pressione di 2° stadio

Gestione delle ulcere da pressione di 3° stadio

Gestione delle ulcere da pressione di 4° stadio

Presentazione del caso clinico: gestione delle ulcere da pressione
"Rientro alla vita" dopo quattro mesi dalla guarigione dell'ulcera da pressione.

Askina® Calgitrol® Paste

Askina® Calgitrol® Paste is a sterile primary dressing consisting of an ionic silver alginate matrix in paste form, designed to treat chronic wounds which are infected or at high risk of infection.   The paste form, due to its water content, provides immediate availability of silver ions. Additionally, the ionic exchange with the wound exudate, delivers a sustained release of ionic silver to the wound bed.1   It is supplied sterile in a 15 g tube. The tube has a cannula to aid application of the paste into tunnels, sinuses, and all deep wounds. 2

Askina® Calgitrol® Ag+

Askina® Calgitrol® Ag+ is a wound dressing that combines antimicrobial silver with strengthening cellulose fiber to manage wound infection and high exudate. The dressing promotes healing in a moist environment.  When applied, Askina® Calgitrol® Ag+ responds by forming a gel on contact with wound exudate. The gelling formation traps, locks in and kills the bacteria away from the wound bed. It contains encapsulated nanoparticles of ionic silver encrusted into the strengthening cellulose fiber. The nanoparticles act as a reservoir of ionic silver and are released gradually in contact with wound fluid to kill bacteria and microorganisms within the dressing.Under the supervision of a healthcare professional, Askina® Calgitrol® Ag+ antimicrobial wound dressings may be used for:All agesModerately to heavily exuding woundsChronic wounds, e. g. leg ulcers, pressure ulcers and diabetic ulcersSurgical wounds, e. g. post-operative, wounds left to heal by secondary intent and donor sitesTraumatic wounds, e. g. abrasions and lacerationsPartial thickness burnsIf required, the dressings can be used in conjunction with a suitable moisture-retaining secondary dressing to keep the product in place and/or under compression.

Askina® Foam

Askina® Foam is a soft, two-layered, non-adherent dressing that is designed to absorb and retain moderate to high wound exudate while providing a moist wound environment to promote healing. The outer vapor-permeable polyurethane film physically protects the wound from water and bacteria.The soft and flexible polyurethane foam provides an excellent conformability to adapt to different wound locations on the body.Askina® Foam wound dressing may be used for: Moderately to heavily exuding woundsChronic wounds, e. g. pressure ulcers, leg and foot ulcersTraumatic wounds, e. g. first and second-degree burns, and surgical wounds

Askina® Heel

Askina® Heel is a heel-shaped, two-layered, non-adherent foam dressing designed to cover the heel and the malleolus. The gentle polyurethane foam can reduce pressure on wounds in this area as well as provide a moist wound environment to promote wound healing. The waterproof outer layer protects the wound from dirt and bacteria. The product includes the option to use a foam security strap and two self-adhesive hooks that keep the dressing in place even during movement, avoiding the need to use an additional fixation device.Askina® Heel is indicated for the management of a wide range of moderately to highly exuding wounds, mainly for exudate absorption at the heel site. 

Askina® DresSil

Askina® DresSil is a non-bordered, self-adherent soft silicone wound dressing. It absorbs exudate from the wound through silicone perforations and provides a moist wound healing environment to promote wound healing.  The wound contact layer made of silicone reduces pain and trauma during dressing changes, enhancing patient comfort. The waterproof outer layer protects the wound from dirt and bacteria. The soft polyurethane foam conforms to the natural contours of the body making the dressing comfortable to wear, while the waterproof outer layer protects the wound from dirt and bacteria. Askina® DresSil is designed for a wide range of exuding wounds, such as:  Leg and foot ulcersPressure ulcers  Traumatic wounds, e.g. skin tears  Secondary healing woundsMaterial  Askina® DresSil is composed of three layers:  Layer 1: Outer polyurethane filmLayer 2: Absorbent polyurethane foamLayer 3: Silicone adhesive 

Askina® DresSil Active Heel

Askina® DresSil Active Heel is a heel multilayer silicone dressing with border designed to provide active exudate management. Its multilayer structure improves exudate retention and absorption while maintaining the adequate moisture level in the wound1. This may reduce the frequency of dressing changes, thereby saving nursing time and allowing more time to be dedicated to patients and their care2. Askina® DresSil Active Heel is designed for a wide range of exuding wounds such as:Pressure ulcersLeg and foot ulcersTraumatic wounds (e.g. skin tears)Surgical wounds It can also be used on dry/necrotic wounds in combination with gels. The dressing may also be used as part of a prophylactic therapy to help prevent skin damage, e.g. pressure ulcers. Material Askina® DresSil Active Heel, thanks to its multilayer structure, is designed to offer effective exudate management of chronic wounds: Layer 1: Semi-transparent film with 1 cm apart dots for the Active Exudate Monitoring SystemLayer 2: Superabsorbent layer to absorb and lock in exudateLayer 3: Exudate distribution layer to facilitate quick exudate movement from the foam to the superabsorbent layerLayer 4: Thin foam layer that enables vertical absorption while maintaining a moist environment conducive to wound healingLayer 5: Silicone layer to provide secure fixation while conforming to body contours

Askina® DresSil Active Sacrum

Askina® DresSil Active Sacrum is a sacrum multilayer silicone dressing with border designed to provide active exudate management. Its multilayer structure improves exudate retention and absorption while maintaining the adequate moisture level in the wound1. This may reduce the frequency of dressing changes, thereby saving nursing time and allowing more time to be dedicated to patients and their care2. Askina® DresSil Active Sacrum is designed for a wide range of exuding wounds such as:Pressure ulcersLeg and foot ulcersTraumatic wounds (e.g. skin tears)Surgical woundsIt can also be used on dry/necrotic wounds in combination with gels. The dressing may also be used as part of a prophylactic therapy to help prevent skin damage, e.g. pressure ulcers. MaterialAskina® DresSil Active Sacrum, thanks to its multilayer structure, is designed to offer effective exudate management of chronic wounds:Layer 1: Semi-transparent film with 1 cm apart dots for the Active Exudate Monitoring SystemLayer 2: Superabsorbent layer to absorb and lock in exudateLayer 3: Exudate distribution layer to facilitate quick exudate movement from the foam to the superabsorbent layerLayer 4: Thin foam layer that enables vertical absorption while maintaining a moist environment conducive to wound healingLayer 5: Silicone layer to provide secure fixation while conforming to body contours

Linovera®

Chronic wounds are a major global medical concern,1 significantly impacting patients’ quality of life,2 while also affecting close family and relatives. Chronic wounds also cause considerable financial burden3 on the healthcare system and society.Topical preventive measures such as Linovera® oil are needed to avoid higher healthcare expenditures and preserve patients’ health. They can be used with the goal of promoting integrity of the skin and providing essential moisturizing.4HOFA-containing topical formulations have become an ideal therapeutic option that is part of the clinical protocols for nursing action in the prevention and treatment of ulcers.5 Linovera® is a skin care oil composed of: Hyperoxygenated fatty acids (HOFA) originated from sunflower oil naturally rich in linoleic acid,6 an essential fatty acid important in the maintenance of epidermal integrity and the natural skin’s water barrier.7 Some of the HOFA properties can increase skin resistance, reduce dehydration, reduce friction and pressure forces8 and improve microcirculation.9Vegetable extracts formulated to provide additional benefits such as skin conditioning, humectant, and tonic, enhancing the activity of the product. Thanks to its content of HOFA and vegetable extracts, Linovera® oil can be useful in the prevention of skin breakdown (e.g. prevention of stage 1 pressure ulcers) or in the management of already impaired skin,8,10 helping to provide the best care for your patients. CompositionHyperoxygenated fatty acids derived from sunflower oil (emollient)Aloe Barbadensis extract (skin conditioning, emollient, humectant)Asian Centella oil extract (skin conditioning, skin tonic, soothing agent)Rosemary essential oil (organoleptic) IndicationsLinovera® oil is indicated: For patients whose skin integrity is at riskFor prevention of pressure ulcers, vascular ulcers and diabetic foot ulcersFor treatment of stage 1 pressure ulcers

[1] Graves N, Birrell F, Whitby M. Effect of pressure ulcers on length of hospital stay. Infect Control Hosp Epidemiol. 2005 Mar;26(3):293-7. doi: 10.1086/502542. PMID: 15796283.

[2] Sebba Tosta de Souza DM, Veiga DF, Santos ID, Abla LE, Juliano Y, Ferreira LM. Health-Related Quality of Life in Elderly Patients With Pressure Ulcers in Different Care Settings. J Wound Ostomy Continence Nurs. 2015 Jul-Aug;42(4):352-9. doi: 10.1097/WON.0000000000000142. PMID: 26135820.

[3] Labeau SO, Afonso E, Benbenishty J, Blackwood B, Boulanger C, Brett SJ, Calvino-Gunther S, Chaboyer W, Coyer F, Deschepper M, François G, Honore PM, Jankovic R, Khanna AK, Llaurado-Serra M, Lin F, Rose L, Rubulotta F, Saager L, Williams G, Blot SI; DecubICUs Study Team; European Society of Intensive Care Medicine (ESICM) Trials Group Collaborators. Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study. Intensive Care Med. 2021 Feb;47(2):160-169. doi: 10.1007/s00134-020-06234-9. Epub 2020 Oct 9. Erratum in: Intensive Care Med. 2021 Apr;47(4):503-520. PMID: 33034686; PMCID: PMC7880913.

[4] Munoz N, Posthauer ME, Cereda E, Schols JMGA, Haesler E. The Role of Nutrition for Pressure Injury Prevention and Healing: The 2019 International Clinical Practice Guideline Recommendations. Adv Skin Wound Care. 2020 Mar;33(3):123-136. doi: 10.1097/01.ASW.0000653144.90739.ad. PMID: 32058438.

[5] see current IFU Linovera®

[6] see current IFU Linovera® Emulsion

[7] see current IFU Askina® Heel

[8] see current IFU Prontosan® Wound Irrigation Solution

[9] see current IFU Prontosan® Wound Gel 

[10] see current IFU Prontosan® Debridement Pad

[11] see current IFU Askina® Calgitrol Paste

[12] see current IFU Askina® Calgitrol AG

[13] see current IFU Askina® Carbosorb

[14] see current IFU Askina® DresSil Sacrum

[15] see current IFU Askina® DresSil Heel

[16] see current IFU Askina® DresSil

[17] see current IFU Askina® DresSil Border

[18] see current IFU Askina® Foam

[19] see current IFU Askina® Barrier Cream

[20] see current IFU Askina® Barrier Film Swabs

[21] see current IFU Askina® Barrier Film Spray

[22] see current IFU Askina® Sorb 

[23] Defloor T, De Bacquer D, Grypdonck MH. The effect of various combinations of turning and pressure reducing devices on the incidence of pressure ulcers. Int J Nurs Stud. 2005 Jan;42(1):37-46. doi: 10.1016/j.ijnurstu.2004.05.013. PMID: 15582638.

[24] Gefen A.: How much time does it take to get a pressure ulcer? Integrated evidence from human, animal, and in vitro studies. Ostomy Wound Manage. 2008 Oct;54(10):26-8, 30-5. PMID: 18927481.